MENU
MAY 01, 2017 8:00 AM PDT

Using iPSCs and Genome Engineering to Build Disease Models

Speaker
  • Director of R&D, Cell Biology, Thermo Fisher Scientific
    Biography
      David Piper has led teams at Thermo Fisher Scientific for over 10 years in the development of products and services for cellular engineering, biochemical assays and cell-based assays for the screening of multiple target classes (ion channels, GPCRs, kinases, nuclear receptors, pathway profiling) and next generation solutions for drug discovery using iPSC-based approaches. These efforts are directed at generating more patho-physiologically relevant cell models through the use of reprogramming, stem cell culture, characterization and differentiation, genomic engineering and assay development. Currently, as an R&D Director for the Cell Biology and Synthetic Biology businesses, he leads teams that provide molecular biology and cellular biology services including cDNA Library synthesis, high-throughput cloning, CRISPR and TALN design and generation, LENTI virus generation, BacMam virus generation, cell engineering (multiple delivery and integration platforms), assay development (multiple detection formats), LentiArray™ CRISPR libraries and functional genomics screening using either siRNA or CRISPR based approaches.

    Abstract

    Developing therapies for human diseases continues to face obstacles, particularly in translating targets or compounds identified by in vitro screening campaigns to valid targets or efficacious and safe compounds once tested in humans.  Here we discuss strategies that leverage induced pluripotent stem cells (iPSCs) to increase the relevance of cell models for these in vitro approaches.  We review current advances in genome engineering and how to leverage a portfolio of these tools to generate knock-out and knock-in models for use in target or compound identification.  Specifically, we demonstrate this approach with induced pluripotent stem cells (iPSCs) to build isogenic disease models, which can be further differentiated to various cell types of interest that are more directly related to a disease area than commonly used immortalized cell lines.  We expect strategies combining genome engineering and stem cells to provide platforms for more robust disease models that will provide more predictable translation of in vitro to in vivo results.

     


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    AUG 27, 2020 7:00 AM PDT
    C.E. CREDITS
    AUG 27, 2020 7:00 AM PDT
    DATE: August 27, 2020 TIME: 7:00am PT Novel anti-viral medications, including biologics and small molecule inhibitors, as well as serologic diagnostic tool sets are in urgent demand to fight...
    MAY 01, 2017 8:00 AM PDT

    Using iPSCs and Genome Engineering to Build Disease Models


    Specialty

    Molecular Biology

    Biotechnology

    Cell Biology

    Cell Culture

    Neuroscience

    Genetics

    Cancer Research

    Gene Expression

    Clinical Research

    Dna

    Immunology

    Crispr-Cas9

    Pcr/rt-Pcr/real-Time Pcr

    Biomarkers

    Gene Editing

    Geography

    Europe47%

    North America25%

    Asia22%

    South America3%

    Oceania1%

    Africa1%

    Registration Source

    Website Visitors100%

    Job Title

    Research Scientist19%

    Student14%

    Post Doc14%

    Educator/Faculty10%

    Medical Doctor/Specialist8%

    Executive8%

    Scientist6%

    Facility/Department Manager5%

    Biologist5%

    Engineer3%

    Lab Management2%

    Marketing/Sales2%

    Veterinarian2%

    Clinical Laboratory Scientist2%

    Animal Care Lab Technician2%

    Organization

    Academic Institution23%

    Research Institute6%

    Pharmaceutical Company5%

    Veterinary School4%

    Medical Center4%

    Hospital4%

    Biotech Company4%

    Medical School3%

    Contract Research Organization (Cro)3%

    Life Science Company3%

    Government3%

    Government/public1%

    Medical Device Company1%

    Distribution/sales1%

    Other5%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more